- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Simon Rule, MD: The Impact of Subcutaneous Rituximab on Clinical Practice
Simon Rule, MD, Plymouth University Medical School, discusses how subcutaneous rituximab has impacted clinical practice.
Transcript:
In my own hospital, we’ve been using subcutaneous rituximab for quite a few years now. We did the early studies, and it’s made a massive difference, not just with respect to your day unit, your nursing resource, the chair time, but also with respect to the patients.
So, we did a time-and-motion study, which was published some time ago, comparing intravenous with subcutaneous. We actually timed patients from the minute they walked in the hospital door to the time they walked out.
Whilst on the face of it, an [intravenous] infusion is 90 minutes, the patient’s actually in the hospital for nearly 4 horus by the time they’re in and out. With a subcutaneous, you literally can give and go. You don’t have to give any prophylaxis. So the patient has the injection, it takes about 5 minutes, and they can leave. So that’s a big, big difference. It’s a fixed syringe, so you don’t have to preorder it.
You can give it outside the hospital setting, of course, and the big difference we saw is maybe not so much for the patient but for the relative; because these patients are often elderly, they’ve got their son or daughter taking off work to go to the hospital. If it only takes half an hour rather than all afternoon, then that’s a big, big impact. I think that’s often not looked at particularly. We just focus on how long the patient’s in the chair getting the drug for, but actually, it’s a big impact.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
